home / compounds / Cagrilintide
Cagrilintide
AM833
Amylin analogue, mainly studied combined with semaglutide.
What it is
A long-acting amylin analogue investigated largely as a combination therapy.
What it does
Amylin signalling contributes to satiety through a pathway distinct from GLP-1, which is the rationale for combining the two.
Does it work?
Clinical development is ongoing, mostly as part of a combination product. Standalone evidence is thinner than the combination data.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Promotes satiety through the amylin pathway | supported |
| Adds weight loss when combined with semaglutide | partially true |
| Proven as a standalone weight-loss therapy | weak evidence |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
391 publications indexed, but only 18 randomised controlled trials and 44 registered interventional studies. Human evidence exists but is thin.
query: "Cagrilintide" · checked 2026-08-07
Most-cited literature
-
Anti-obesity drug discovery: advances and challenges
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. · Nat Rev Drug Discov 2022 · 710 citations
-
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. · Signal Transduct Target Ther 2024 · 431 citations
-
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker DJ. · Mol Metab 2022 · 377 citations
-
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. · BMJ 2024 · 304 citations
Regulatory status
Formal, dated regulatory actions.
WADA — Prohibited List 2026
Prohibited in sport — WADA S0 (substance without any health-authority approval)
Common questions
What is CagriSema?
The clinical combination of cagrilintide with semaglutide, developed as a single weekly product. Most cagrilintide evidence comes from this programme.
Does cagrilintide work on its own?
Standalone data is thinner than the combination data. The amylin pathway is a real satiety mechanism, but the strong results reported are largely combination results.
Is it approved anywhere?
Not as of our last review. It remains in clinical development.
Related compounds
Semaglutide
GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.
Tirzepatide
Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.
Retatrutide
Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.